Arcosa, Inc., together with its subsidiaries, provides infrastructure-related products and solutions for the construction, engineered structures, and transportation markets in the United States. The company operates through three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment offers natural and recycled aggregates; specialty materials; and construction site support equipment, including trench shields and shoring products for residential and non-residential construction, and specialty/other products, as well as for infrastructure construction. The Engineered Structures segment offers utility structures, wind towers, traffic and lighting structures, and telecommunication structures for electricity transmission and distribution, wind power generation, highway road construction, and wireless communication markets. This segment sells its products to contractors and distributors serving state Departments of Transportation and state and municipality agencies. The Transportation Products segment offers inland barges, fiberglass barge covers, winches, marine hardware, and other transportation and industrial equipment to the commercial marine transportation companies, lessors, and industrial shippers. Arcosa, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Arcosa Inc.

In a report released today, Bernd Klanten from Barclays maintained a Buy rating on Acast AB, with a price target of SEK34.00. According to TipRanks...

Acast AB (0PN) Receives a Buy from Barclays

An update from Acast AB ( ($SE:ACAST) ) is now available. Acast AB will publish its year-end report for 2025 on Wednesday 11 February at 07:00 CET ...

Acast Schedules Webcast for 2025 Year-End Results

Barclays analyst Adam Seiden maintained a Buy rating on Arcosa today and set a price target of $115.00. According to TipRanks, Seiden is a 5-star a...

Arcosa (ACA) Gets a Buy from Barclays

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX – Research Report) and ACADIA...

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rapport Therapeutics, Inc. (RAPP – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Bausch + Lomb Corporation (BLCO)

Acast AB ( ($SE:ACAST) ) has issued an update. Acast has entered an exclusive ad sales and distribution partnership with Perfect Day Media, one of ...

Acast Expands Swedish Podcast Footprint With Exclusive Perfect Day Media Ad Sales Deal

AcadeMedia AB ( ($SE:ACAD) ) just unveiled an update. AcadeMedia has scheduled the release of its quarterly report for the period July–December 202...

AcadeMedia Sets 2 February Date for Q2 2025/26 Report and Investor Webcast

Yancoal Australia ( ($AU:YAL) ) has shared an update. Yancoal Australia reported record quarterly and full-year production for 2025, with 18.9 mill...

Yancoal Sets Production Record and Lifts Cash Pile on Strong Q4 Prices

RBC Capital analyst Anke Reingen maintained a Hold rating on Credit Agricole yesterday and set a price target of €19.00. Reingen covers the Financi...

RBC Capital Sticks to Their Hold Rating for Credit Agricole (0HAI)

The latest announcement is out from Yancoal Australia ( ($AU:YAL) ). Yancoal Australia has announced it will release its fourth-quarter 2025 quarte...

Yancoal Sets Date for 4Q 2025 Report and Investor Webcast

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cormedix (CRMD – Research Report), BioMarin Pharma...

Analysts Conflicted on These Healthcare Names: Cormedix (CRMD), BioMarin Pharmaceutical (BMRN) and ACADIA Pharmaceuticals (ACAD)

The latest announcement is out from Yancoal Australia ( ($AU:YAL) ). Yancoal Australia has lodged its monthly return for equity securities and Hong...

Yancoal Reports No Share Capital Changes in December HKEX Filing

Spotify ($SPOT) is making an aggressive play to dominate the video market and take on giants like Google’s ($GOOGL) YouTube. On Wednesday, the comp...

Spotify Stock Ticks Up after Disclosing a Staggering $10 Billion Spend on Creator Tools to Rival YouTube

In a report released today, Ashwani Verma from UBS maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $40.00. According to T...

UBS Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)

Guoyuan Securities (HK) analyst maintained a Buy rating on AAC Technologies Holdings yesterday and set a price target of HK$55.56. Currently, the a...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACA	$116.38	+1.67%	163.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACA	$116.38	+1.7%	163.40K
3
4
5
6

ACA

ACA

Get Arcosa Inc. Data in Excel

Get Arcosa Inc. Data in Excel